Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunocore Holdings Plc ADR (NQ: IMCR )

58.46 +0.46 (+0.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 403,551
Open 57.75
Bid (Size) 23.18 (2)
Ask (Size) 92.70 (2)
Prev. Close 58.00
Today's Range 56.10 - 58.94
52wk Range 42.21 - 76.98
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immunocore announces upcoming presentation and posters at ASCO 2024
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Via Benzinga

Performance

YTD
-18.40%
-18.40%
1 Month
-8.05%
-8.05%
3 Month
-16.46%
-16.46%
6 Month
+36.43%
+36.43%
1 Year
-0.56%
-0.56%

More News

Read More
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
Via InvestorPlace
Immunocore presented two posters at CROI 2024
From Immunocore Holdings Limited
Via GlobeNewswire
Key Takeaways From Immunocore Hldgs Analyst Ratings
Via Benzinga
Immunocore Hldgs's Earnings: A Preview
Via Benzinga
Immunocore's Pipeline Is Among The Strongest In Broader Biotech Universe: Analyst
Via Benzinga
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
From Immunocore Holdings Limited
Via GlobeNewswire
5 Analysts Have This to Say About Immunocore Hldgs
Via Benzinga
Analyst Ratings for Immunocore Hldgs
Via Benzinga
Immunocore Prices Upsized Convertible Senior Notes Offering
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore Announces Proposed Convertible Senior Notes Offering
From Immunocore Holdings Limited
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings Limited
Via GlobeNewswire
AGC Biologics to Prepare Late Phase and Commercial Runs for Immunocore
Via News Direct
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
From Immunocore Holdings Limited
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.